Page last updated: 2024-10-16

bromide and Hyperidrosis

bromide has been researched along with Hyperidrosis in 6 studies

Bromides: Salts of hydrobromic acid, HBr, with the bromine atom in the 1- oxidation state. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)

Research Excerpts

ExcerptRelevanceReference
"A phase 3 study was conducted to verify the efficacy and safety of 5% sofpironium bromide (BBI-4000) gel (hereinafter referred to as sofpironium) administrated for 6 weeks in Japanese patients with primary axillary hyperhidrosis."9.41A phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group study of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis. ( Abe, Y; Akamatsu, M; Egami, Y; Fujimoto, T; Hamaguchi, M; Hanafusa, T; Hattori, N; Horiuchi, Y; Igarashi, M; Ishikoh, A; Kanda, H; Kinoshita, M; Kitahara, H; Kume, A; Maruyama, R; Matsuda, T; Matsuo, K; Mizutani, H; Murakami, Y; Nakasu, I; Omi, T; Takayama, S; Watanabe, C; Yokozeki, H; Yorozuya, T; Yoshioka, A, 2021)
"A long-term study was conducted in Japanese patients with primary axillary hyperhidrosis who completed the preceding 6-week phase III, confirmatory study of 5% sofpironium bromide gel (hereinafter referred to as sofpironium) to evaluate the safety and efficacy of 52-week treatment with sofpironium."9.41A phase III, 52-week, open-label study to evaluate the safety and efficacy of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis. ( Abe, Y; Akamatsu, M; Egami, Y; Fujimoto, T; Hamaguchi, M; Hanafusa, T; Hattori, N; Horiuchi, Y; Igarashi, M; Ishikoh, A; Kanda, H; Kinoshita, M; Kitahara, H; Kume, A; Maruyama, R; Matsuda, T; Matsuo, K; Mizutani, H; Murakami, Y; Nakasu, I; Omi, T; Takayama, S; Watanabe, C; Yokozeki, H; Yorozuya, T; Yoshioka, A, 2021)
"A phase 3 study was conducted to verify the efficacy and safety of 5% sofpironium bromide (BBI-4000) gel (hereinafter referred to as sofpironium) administrated for 6 weeks in Japanese patients with primary axillary hyperhidrosis."5.41A phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group study of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis. ( Abe, Y; Akamatsu, M; Egami, Y; Fujimoto, T; Hamaguchi, M; Hanafusa, T; Hattori, N; Horiuchi, Y; Igarashi, M; Ishikoh, A; Kanda, H; Kinoshita, M; Kitahara, H; Kume, A; Maruyama, R; Matsuda, T; Matsuo, K; Mizutani, H; Murakami, Y; Nakasu, I; Omi, T; Takayama, S; Watanabe, C; Yokozeki, H; Yorozuya, T; Yoshioka, A, 2021)
"A long-term study was conducted in Japanese patients with primary axillary hyperhidrosis who completed the preceding 6-week phase III, confirmatory study of 5% sofpironium bromide gel (hereinafter referred to as sofpironium) to evaluate the safety and efficacy of 52-week treatment with sofpironium."5.41A phase III, 52-week, open-label study to evaluate the safety and efficacy of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis. ( Abe, Y; Akamatsu, M; Egami, Y; Fujimoto, T; Hamaguchi, M; Hanafusa, T; Hattori, N; Horiuchi, Y; Igarashi, M; Ishikoh, A; Kanda, H; Kinoshita, M; Kitahara, H; Kume, A; Maruyama, R; Matsuda, T; Matsuo, K; Mizutani, H; Murakami, Y; Nakasu, I; Omi, T; Takayama, S; Watanabe, C; Yokozeki, H; Yorozuya, T; Yoshioka, A, 2021)
" The soft anticholinergic sofpironium bromide represents the latest expansion of soft drug use in dermatology for the treatment of primary axillary hyperhidrosis (PAH)."4.12SUPPLEMENT ARTICLE: A Novel Drug Delivery Method: Retrometabolic Drug Design. ( Armstrong, A; Chadha, D; Kircik, L; Reddy, R, 2022)

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's6 (100.00)2.80

Authors

AuthorsStudies
Gregoriou, S1
Tsiogka, A1
Kontochristopoulos, G1
Offidani, A1
Campanati, A1
Armstrong, A1
Reddy, R1
Chadha, D1
Kircik, L1
Fujimoto, T3
Okatsu, H1
Miyama, H1
Paik, J1
Yokozeki, H2
Abe, Y2
Igarashi, M2
Ishikoh, A2
Omi, T2
Kanda, H2
Kitahara, H2
Kinoshita, M2
Nakasu, I2
Hattori, N2
Horiuchi, Y2
Maruyama, R2
Mizutani, H2
Murakami, Y2
Watanabe, C2
Kume, A2
Hanafusa, T2
Hamaguchi, M2
Yoshioka, A2
Egami, Y2
Matsuo, K2
Matsuda, T2
Akamatsu, M2
Yorozuya, T2
Takayama, S2

Reviews

1 review available for bromide and Hyperidrosis

ArticleYear
Sofpironium Bromide: First Approval.
    Drugs, 2020, Volume: 80, Issue:18

    Topics: Bromides; Cholinergic Antagonists; Gels; Humans; Hyperhidrosis; Japan

2020

Trials

2 trials available for bromide and Hyperidrosis

ArticleYear
A phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group study of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis.
    The Journal of dermatology, 2021, Volume: 48, Issue:3

    Topics: Adult; Axilla; Bromides; Double-Blind Method; Female; Humans; Hyperhidrosis; Japan; Male; Severity o

2021
A phase III, 52-week, open-label study to evaluate the safety and efficacy of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis.
    The Journal of dermatology, 2021, Volume: 48, Issue:8

    Topics: Adult; Bromides; Double-Blind Method; Female; Humans; Hyperhidrosis; Japan; Male; Treatment Outcome

2021

Other Studies

3 other studies available for bromide and Hyperidrosis

ArticleYear
Sofpironium bromide: an investigational agent for the treatment of axillary hyperhidrosis.
    Expert opinion on investigational drugs, 2022, Volume: 31, Issue:1

    Topics: Axilla; Bromides; Cholinergic Antagonists; Drugs, Investigational; Humans; Hyperhidrosis; Treatment

2022
SUPPLEMENT ARTICLE: A Novel Drug Delivery Method: Retrometabolic Drug Design.
    Journal of drugs in dermatology : JDD, 2022, Apr-01, Volume: 21, Issue:4

    Topics: Bromides; Cholinergic Antagonists; Drug Design; Humans; Hyperhidrosis; Pharmaceutical Preparations

2022
Two-week prospective observational study of 5% sofpironium bromide gel in Japanese patients with primary axillary hyperhidrosis.
    The Journal of dermatology, 2022, Volume: 49, Issue:6

    Topics: Adult; Axilla; Bromides; Cholinergic Antagonists; Female; Humans; Hyperhidrosis; Japan; Male; Prospe

2022